Global Deferasirox Market Growth 2023-2029

Global Deferasirox Market Growth 2023-2029

Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
LPI (LP Information)' newest research report, the “Deferasirox Industry Forecast” looks at past sales and reviews total world Deferasirox sales in 2022, providing a comprehensive analysis by region and market sector of projected Deferasirox sales for 2023 through 2029. With Deferasirox sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Deferasirox industry.
This Insight Report provides a comprehensive analysis of the global Deferasirox landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Deferasirox portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Deferasirox market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Deferasirox and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Deferasirox.
The global Deferasirox market size is projected to grow from US$ 2670.4 million in 2022 to US$ 3675.2 million in 2029; it is expected to grow at a CAGR of 3675.2 from 2023 to 2029.
The major global manufacturers of Dillaros are Novartis, Cipla, Natco Pharma and Sun Pharma, among which Novartis is the industry leader with a market share of around 99%. North America is the largest spending region, with 30 per cent of the market, followed by Europe with 25 per cent.
This report presents a comprehensive overview, market shares, and growth opportunities of Deferasirox market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
500 mg/Tablet
250 mg/Tablet
125 mg/Tablet
Others
Segmentation by application
Transfusional Iron Overload
NTDT Caused Iron Overload
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Cipla
Natco Pharma
Sun Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Deferasirox market?
What factors are driving Deferasirox market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Deferasirox market opportunities vary by end market size?
How does Deferasirox break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.